Lilly And GSK/Vir Antibody Combo Reduces COVID-19 Viral Load

 
• By Joseph Haas
  
Generate a summary of this article
Listen to this article
Beta

Top-line Phase II data show that a combo of bamlanivimab and VIR-7831, neutralizing antibodies to the SARS-CoV-2 spike protein, yielded a relative 70% reduction in viral load.

Microscopic cells of Coronavirus
Lilly/Vir/GSK antibody combo shows ability to reduce COVID-19 viral load

Eli Lilly and Company and partners GlaxoSmithKline plc and Vir Biotechnology, Inc. reported top-line Phase II data on 29 March indicating that a combination of the former’s bamlanivimab and the latter two companies’ VIR-7831 can reduce high viral load in low-risk COVID-19 patients. The companies asserted that the combination might provide benefit to patients who contract circulating variants of the SARS-CoV-2 virus that may be tougher to treat than the initial strain of the virus.

Both bamlanivimab and VIR-7831 are neutralizing antibodies that bind to different regions of the SARS-CoV-2 spike protein. Lilly’s bamlanivimab has...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from COVID-19

New COVID-19 Vaccines Shipping Soon, After Rapid Pivot To Address New Strain

 
• By Alaric DeArment

Pfizer/BioNTech and Moderna rapidly adapted Comirnaty and Spikevax for the 2024-2025 season to address the KP.2 variant after the US FDA had advised them to target JN.1 in June.

Pfizer/BioNTech Combo Vaccine Shows Partial Flu Efficacy

 
• By Alaric DeArment

The companies said their combination mRNA vaccine showed protection against SARS-CoV-2 and influenza A, but not influenza B.

AstraZeneca Moves To Join Invyvid In COVID-19 Prevention

 
• By Elizabeth Cairns

The UK giant’s COVID-19 prophylactic sipavibart could soon reach Europe and competition is sparse.    

Stock Watch: Thoroughly Moderna Missteps

 
• By Andy Smith

When life hands a biotech company the equivalent of good grapes, the expectations are for its products to be the equivalent of fine wine. Before that Moderna looks likely to make lemonade.

More from Scrip

EHA: Lilly’s Jaypirca Posts First Phase III Triplet Win In CLL While BTK Degraders Advance - Clone

Lilly's first Phase III triplet win opens the door to a label expansion in BTK-pretreated CLL, with analysts suggesting Jaypica could attain blockbuster status. However, the window to capitalize may be brief as next-generation BTK degraders close in with head-to-head trials.

Top 10 Drugs Q1 2026: New Sheriff In Town As Mounjaro Unseats Keytruda

Mounjaro, Eliquis, and Darzalex buck the Q1 trend to make gains